Iterum Therapeutics shares fall 10.11% intraday despite launching ORLYNVAH for uUTIs.

Iterum Therapeutics Plc dropped 10.11% in intraday trading, despite the company launching ORLYNVAH, the first oral penem antibiotic commercially available in the U.S. for treating uncomplicated urinary tract infections (uUTIs) in adult women. The FDA approved ORLYNVAH in October 2024, marking the first new branded product introduced in the U.S. for uUTI in over 25 years.